Company Insights

MEDP customer relationships

Explore interactive graphBrowse insights index
MEDP customer relationship map

Medpace (MEDP) — Customer Relationships: CinRx, LIB Therapeutics, and Zelluna

Medpace is a global contract research organization that monetizes by delivering end-to-end clinical development services under master service agreements (MSAs), task orders and time-and-materials engagements, with supplementary revenue from proprietary systems such as ClinTrak. The company books revenue as it performs clinical trial services and carries a multi-billion dollar backlog of performance obligations, giving investors visibility into near-term revenue conversion and an exposure profile concentrated in smaller and mid-sized biopharmaceutical sponsors. For an investor-focused map of these customer linkages, visit NullExposure.

How Medpace structures customer work and what that means for revenue visibility

Medpace sells operational execution and regulatory management across Phases I–IV, structuring engagements through a combination of MSAs that establish commercial terms and recurring task orders that specify program-level work. The FY2025 disclosures state that contracts "range in duration from a few months to several years," which produces a hybrid contracting posture: short-term task work layered onto longer-term MSAs that create predictable follow-on demand. The company also reports approximately $3.6 billion of performance obligations for active projects as of December 31, 2025, which translates to measurable revenue backlog.

Company-level signals you should incorporate into underwriting and operational oversight:

  • Contracting posture: Medpace operates a mix of short- and long-term contracts — MSAs provide framework stability while task orders drive quarter-to-quarter revenue recognition (FY2025 10‑K).
  • Client concentration by size: For FY2025, 82% of net revenue came from small biopharmaceutical companies and 13% from mid-sized biopharmaceutical companies, with the remainder from large pharma; this is a growth-rich but credit-sensitive customer base (FY2025 10‑K).
  • Geographic footprint: Medpace is global, with principal operations in North America, Europe and Asia and material activity in other continents — a regional diversification that reduces single-market volatility (FY2025 10‑K).
  • Role and criticality: The company is a service provider delivering essential trial execution and data management; sponsors depend on these services to meet regulatory timelines and milestones (FY2025 10‑K).
  • Product mix: Primary revenue derives from clinical services, with software access (ClinTrak) offered to customers as part of service delivery — a modest but strategic element that supports customer retention (FY2025 10‑K).

For deeper mapping of these client ties and their contract archetypes, see NullExposure.

Customer relationships recorded in filings and press

Medpace’s public disclosures and press coverage identify specific partner relationships indicative of its standard commercial model: MSAs plus task orders for clinical services, and news-driven trial partnerships with emerging biotech sponsors. Below are the relationships found in recent sources.

CinRx Pharma

Medpace and CinRx have executed several task orders for clinical trial–related services, consistent with Medpace’s task-order execution model under an overarching contractual relationship. This is recorded in Medpace’s FY2025 Form 10‑K. According to the FY2025 10‑K, these task orders represent operational engagements to execute protocol-specific trial activities.

LIB Therapeutics LLC

Medpace entered into an MSA dated November 24, 2015 with LIB Therapeutics, and has subsequently executed multiple task orders to perform clinical trial services under that agreement, per the FY2025 Form 10‑K. The disclosure underscores Medpace’s use of standing agreements to capture repeat work from a commercial-stage partner.

Zelluna

Press reporting in early 2026 documents a clinical partnership between Medpace and Zelluna to support the first clinical trial of Zelluna’s ZI‑MA4‑1 candidate, reflecting a typical CRO–emerging-biotech sponsor relationship announced via press release. Multiple MarketScreener notices in March 2026 carried the Zelluna announcement that Medpace will support that initial trial, signaling a new active engagement reported in FY2026 news coverage.

What these relationships signal for investors

The three relationships conform to Medpace’s repeatable commercial playbook: MSAs (LIB), task orders (CinRx and LIB) and announced trial partnerships (Zelluna). Taken together they highlight several investment-relevant dynamics:

  • Revenue visibility via backlog and task-work conversion. MSAs plus task orders produce a steady pipeline of work that converts into revenue as trial milestones are achieved; the reported $3.6 billion of remaining performance obligations as of FY2025 is material evidence of that visibility.
  • Concentration toward smaller sponsors drives growth and volatility. With the bulk of revenue from small biopharma (82% in FY2025), Medpace’s top line benefits from a vibrant early-stage pipeline but carries higher counterparty credit risk and milestone sensitivity versus a portfolio dominated by large pharmas.
  • Operational criticality creates pricing leverage but increases delivery risk. As the executing partner, Medpace is tied to sponsors’ timelines; successful delivery enhances retention and upsell, while trial delays or regulatory issues translate into direct revenue deferral and potential reputational costs.
  • Software as retention tool. ClinTrak access is supplementary to services and acts as a modest lock-in and efficiency lever for trial execution workflows.

If you want a practical breakdown of counterparties and contract types for modeling revenue conversion and credit exposure, visit NullExposure.

Risk vectors and monitoring priorities

For active investors and operators, monitoring should focus on:

  • Client credit health among small- and mid-sized sponsors due to higher reliance on external capital for trial funding.
  • Task-order cadence versus backlog burn rate to reconcile reported performance obligations with actual revenue recognition and cash collections.
  • Execution risk on newly announced trials such as the Zelluna ZI‑MA4‑1 program, since first-in-human and early-phase readouts materially influence sponsor behaviour and follow-on business.
  • Geopolitical/regulatory developments across major operating regions that can slow site activation or data flow.

Bottom line for investors

Medpace demonstrates a classic CRO commercial model: long-term MSAs underpin client relationships while task orders and press-announced partnerships convert backlog into revenue. The disclosed relationships with CinRx, LIB Therapeutics and Zelluna collectively reflect repeatable contract mechanics, active engagement coverage across sponsor types, and ongoing exposure to the higher-growth but credit-sensitive small biopharma segment. For portfolio managers and operators building revenue-conversion scenarios or counterparty risk overlays, the combination of a large active backlog, global operations and a small‑sponsor–heavy client mix is the central thesis driving both upside and cyclicality.

For a granular client map and credit signals tied to Medpace’s customer roster, consult NullExposure.